Two studies have shown that SIRT3 blocks cardiac hypertrophy, both in vivo and in vitro, by decreasing oxidative damage, activating FOXO3a-dependent antioxidant-coding genes (catalase, MnSOD) and decreasing ROS levels, which ultimately suppress the activity of transcription factors involved in cardiac hypertrophy [124,136]. Here, SOD2 is linked to cardiac hypertrophy.